Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
India Reality Check In a price-sensitive market like India: Tier 2/3 cities Semaglutide (affordability wins) Metro & obesity clinics Orforglipron (performance + convenience) --- Final Takeaway Orforglipron = Premium Disruptor Semaglutide = Mass-Market Leader Both will coexistbut target very different patient segments
Most people need a short course of a few sessions, with smaller areas usually needing fewer
Robert Kushner: Yeah, it's a very good question
This gradual increase in dosage ensures a more comfortable experience for most patients
US$ 27.66
US$ 24.05
US$ 27.88
